Cancer Venous Thromboembolism (VTE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02073682
Recruitment Status : Completed
First Posted : February 27, 2014
Last Update Posted : October 13, 2017
Information provided by (Responsible Party):
Daiichi Sankyo, Inc.

Brief Summary:
Edoxaban will be similar to dalteparin in preventing recurrence of acute VTE following an initial index event in cancer subjects.

Condition or disease Intervention/treatment Phase
Venous Thromboembolism (VTE) Deep Vein Thrombosis (DVT) Pulmonary Embolism (PE) Cancer Drug: Edoxaban Drug: Dalteparin Phase 4

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1050 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 3b, Prospective, Randomized, Open-label, Blind Evaluator (PROBE) Study Evaluating the Efficacy and Safety of (LMW) Heparin/Edoxaban Versus Dalteparin in Venous Thromboembolism Associated With Cancer
Study Start Date : March 2015
Primary Completion Date : September 15, 2017
Study Completion Date : September 15, 2017

Resource links provided by the National Library of Medicine

Drug Information available for: Edoxaban
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Edoxaban group
Drug: Edoxaban
Active Comparator: Dalteparin group
Drug: Dalteparin

Primary Outcome Measures :
  1. Number of participants with recurrent VTE at end of study [ Time Frame: 6 months ]
    Primary efficacy outcome is incidence of recurrent VTE at end of study

  2. Number of participants with clinically relevant bleeding while on treatment [ Time Frame: 6 months ]
    Primary safety outcome is incidence of clinically relevant bleeding while on treatment

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female subjects with age ≥ 18 years or the otherwise legal lower age according to the country of residence;
  • Confirmed acute lower extremity proximal DVT or PE for which long term treatment with low molecular weight heparin (LMWH) is indicated;
  • Cancer, other than basal-cell or squamous-cell carcinoma of the skin;
  • Able to provide written informed consent.

Exclusion Criteria:

  • Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current (index) episode of DVT and/or PE;
  • Treatment with therapeutic doses of an anticoagulant other than that used for pretreatment of the current (index) VTE episode prior to randomization;
  • Active bleeding or high risk for bleeding contraindicating treatment with LMWH or edoxaban;
  • Any other contraindication listed in the local labeling of dalteparin, enoxaparin, or edoxaban;

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02073682

United States, Florida
Brandon, Florida, United States
United States, Georgia
Jonesboro, Georgia, United States
United States, Michigan
Detroit, Michigan, United States
United States, Virginia
Norfolk, Virginia, United States
Leuven, Vlaams-Brabant, Belgium
Saint-Etienne cedex 2, France
Debrecen, Hajdu-Bihar megye, Hungary
Varese, Italy
Amsterdam, Netherlands
Sponsors and Collaborators
Daiichi Sankyo, Inc.
Study Director: Global Clinical Leader Daiichi Sankyo, Inc.

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Daiichi Sankyo, Inc. Identifier: NCT02073682     History of Changes
Other Study ID Numbers: DU176b-D-U311
2014-004708-30 ( EudraCT Number )
First Posted: February 27, 2014    Key Record Dates
Last Update Posted: October 13, 2017
Last Verified: October 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address:
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Clinical Study Report (CSR)
Analytic Code
Time Frame: Studies for which the medicine and indication have received EU and US marketing approval on or after 01 January 2014 or by the US or EU Health Authorities when regulatory submissions in both regions are not planned and after the primary study results have been accepted for publication.
Access Criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States and the European Union from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.

Additional relevant MeSH terms:
Venous Thromboembolism
Pulmonary Embolism
Venous Thrombosis
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases
Heparin, Low-Molecular-Weight
Factor Xa Inhibitors
Serine Proteinase Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Fibrinolytic Agents
Fibrin Modulating Agents